BSXNYSEHealthcare

BOSTON SCIENTIFIC CORP

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$42.75

-4.23%

Alpha Vantage · 11/6/2026

Industry: Medical DevicesCategory: Domestic Common Stock Primary ClassCurrency: USDNews: 2 recent

Analyze BSX free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+1.7%

3 months

-15.3%

6 months

-20.7%

1 year

-56.8%

Year to date

-55.2%

52-week range

$41.58 – $104.98

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$61.97B

P/E

17.7

P/B

2.4

P/S

2.9

Revenue

$21.07B

Net income

$3.5B

Diluted EPS

2.36

Gross margin

69.10%

Net margin

16.60%

Return on equity

13.90%

Total debt

$11.95B

Cash

$609M

Free cash flow

$3.33B

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$5.14B	$582M	66.70%	11.30%	$868M
Jun 30, 2026	$5.44B	$907M	70.70%	16.70%	$1.28B
Mar 31, 2026	$5.2B	$1.34B	69.40%	25.80%	$171M
Dec 31, 2025	$5.29B	$672M	69.60%	12.70%	$1.01B
Sep 30, 2025	$5.07B	$755M	69.90%	14.90%	$1.16B
Jun 30, 2025	$5.06B	$797M	67.70%	15.70%	$1.13B
Mar 31, 2025	$4.66B	$674M	68.80%	14.50%	$354M
Dec 31, 2024	$4.56B	$566M	67.90%	12.40%	$1.19B

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent BSX news

All market news

Yahoo Finance UK·Nov 4, 202651 signal

RevMedica Appoints Former Boston Scientific Executive Mike Jones as Chief Executive Officer

RevMedica, an innovative medical technology company, has appointed Mike Jones, former Senior Vice President and President of Boston Scientific's Endoscopy division, as its new Chief Executive Officer. Jones will lead the company's strategic direction, focusing on regulatory milestones, clinical development, and commercialization of its intelligent surgical stapling solutions. Founder Tom Wenchell will transition to President and Chief Operating Officer, continuing to oversee product development and technical operations.

Original source

The Business Journals·Oct 28, 202660 signal

Boston Scientific CEO warns company may see no sales growth in 2027

Boston Scientific's CEO, Mike Mahoney, has cautioned that 2027 is expected to be a "trough" year for the medical device manufacturer, potentially seeing no sales growth despite a decade of rapid expansion. This warning comes as the company navigates future market conditions.

Original source